<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411344</url>
  </required_header>
  <id_info>
    <org_study_id>AS.T.R.O.BC01-13</org_study_id>
    <secondary_id>2013-002662-40</secondary_id>
    <nct_id>NCT02411344</nct_id>
  </id_info>
  <brief_title>Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy</brief_title>
  <acronym>PER-ELISA</acronym>
  <official_title>PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the activity of molecular response in endocrine
      sensitive breast cancer HER2+/HR+ patients treated with Pertuzumab-trastuzumab plus
      Ietrozole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is:

        -  to evaluate the rate of pathologic complete response (pCR), as defined as complete
           disappearance of invasive tumor in breast and axillary nodes.

        -  to estimate the percentage of clinical objective responses (cOR) (complete plus partial)
           in the breast, as assessed by ultrasonography (US)

        -  to estimate the percentage of breast conservative surgery

        -  to evaluate the safety profile

        -  To perform correlative biomarker analyses
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathologic complete response</measure>
    <time_frame>At time of surgery, within 3 weeks from the last i.v. therapy</time_frame>
    <description>A pathologic complete response (pCR) is defined the complete absence of infiltrating tumor cells in the breast and in lymph nodes. Residual in situ disease (DCIS) will be included in the pCR category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of clinical objective response.</measure>
    <time_frame>At time of surgery, within 3 weeks from the last i.v. therapy</time_frame>
    <description>The Clinical Response will be defined according to RECIST criteria comparing the tumor size (largest tumor diameter) before and after treatment, as assessed by ultrasound examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Conservative Surgery</measure>
    <time_frame>At time of surgery, within 3 weeks from the last i.v. therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) To version 4.0 will be used</measure>
    <time_frame>Every 21-day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of mutations in the PIK3CA gene</measure>
    <time_frame>Within 4 weeks prior to first dose treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Endocrine Sensitive HER2+/HR+ Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pertuzumab, Trastuzumab, Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles
Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle
Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).</description>
    <arm_group_label>Pertuzumab, Trastuzumab, Letrozole</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary diagnosis of infiltrating breast cancer

          -  HR positivity (ER ≥ 10% and/or PgR ≥10%) and HER2 positivity (IHC 3+ or FISH/CISH
             amplification), as assessed by local laboratory.

          -  Stage II-IIIA

          -  age &gt;18 yrs

          -  ECOG Performance Status 0-1

          -  Postmenopausal status, defined by at least one of the following:

             60 years of age; &lt; 60 years of age and amenorrheic for &gt;/=12 months prior to day 1 &lt;
             60 years of age, without a uterus, and luteinizing hormone (LH) and follicle
             stimulating hormone (FSH) values within postmenopausal range Prior bilateral
             oophorectomy Prior radiation castration with amenorrhea for at least 6 months

          -  Cardiac ejection fraction within the institutional range of normal (as measured by
             echocardiogram or MUGA scan).

          -  Normal organ and marrow function as defined below:

        (leukocytes &gt;=3000/mcL; absolute neutrophil count &gt;=1,500/mcL; platelets &gt;=100,000/mcL;
        total bilirubin within 1.25 x normal institutional limits (with the exception of Gilbert's
        syndrome); AST (SGOT)/ALT(SGPT) within 1.25 x institutional upper limit of normal
        creatinine within normal institutional limits

          -  Availability of tumor tissue suitable for biological and molecular examination before
             starting primary treatment

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Stage IIIB, IIIC, and inflammatory breast cancer

          -  Stage IV breast cancer

          -  Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment
             with HER2 targeting therapies

          -  LVEF below the ULN

          -  Uncontrolled hypertension (systolic &gt;150 mm Hg and/or diastolic &gt;100 mm Hg) or
             clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident
             (CVA)/stroke or myocardial infarction within 6 months prior to first study medication,
             unstable angina, congestive heart failure (CHF) of New York Heart Association (NYHA)
             grade II or higher, or serious cardiac arrhythmia requiring medication.

          -  Received any investigational treatment within 4 weeks of study start.

          -  Subjects with known infection with HIV, HBV, HCV

          -  Known hypersensitivity to any of the study drugs or excipients.

          -  Dyspnoea at rest or other disease requiring continuous oxygen therapy.

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Subjects assessed by the investigator to be unable or unwilling to comply with the
             requirements of the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentina Guarneri, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology 2, Istituto Oncologico Veneto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Luca De Salvo, MD; PhD</last_name>
    <phone>00390498215710</phone>
    <email>gianluca.desalvo@ioveneto.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Soto Parra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Anna</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Angelo Colleoni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Bianchi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto, Oncologia Medica 2</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Guarneri, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggia Emilia</city>
        <state>RE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Bisagni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - IRCCS</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Montemurro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A. O. U. Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Puglisi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULSS 6</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcella Gulisano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giampaolo Tortora, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Oncologico Veneto IRCCS</investigator_affiliation>
    <investigator_full_name>Valentina Guarneri</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>HER2+/HR+</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

